a year ago
TGTX
Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
---|---|---|---|---|---|
Chimerix IncCMRX | +911.85% | $0.84 | $8.54 | 2024-08-13 - 2025-04-17 | Buy |
Chimerix IncCMRX | +721.15% | $1.04 | $8.54 | 2024-11-10 - 2025-04-17 | Buy |
Ideaya Biosciences IncIDYA | +527.23% | $3.82 | $23.96 | 2020-04-05 - 2021-04-06 | Buy |
Tracon Pharmaceuticals IncTCON | +402.81% | $35.60 | $179.00 | 2020-03-09 - 2021-03-10 | Buy |
Inozyme Pharma IncINZY | +354.03% | $0.88 | $4.00 | 2025-04-09 - 2025-07-01 | Buy |
Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
---|---|---|---|---|---|---|
Cullinan Therapeutics IncCGEM | 24 | Buy | $33.00 | +322.54% | Reiterates | 3 months ago |
Valneva SeVALN | 41 | Buy | $17.00 | +192.60% | Reiterates | 3 months ago |
Inozyme Pharma IncINZY | 14 | Buy | $16.00 | +300.00% | Reiterates | 3 months ago |
Nyxoah SaNYXH | 14 | Buy | $15.00 | +93.05% | Reiterates | 3 months ago |
Sab Biotherapeutics IncSABS | 14 | Buy | $6.00 | +248.84% | Reiterates | 3 months ago |
Curis IncCRIS | 17 | Buy | $16.00 | +783.98% | Maintains | 3 months ago |
Sensei Biotherapeutics IncSNSE | 6 | Buy | $80.00 | +785.94% | Reiterates | 3 months ago |
Artiva Biotherapeutics IncARTV | 2 | Buy | $20.00 | +1,142.24% | Reiterates | 3 months ago |
Larimar Therapeutics IncLRMR | 7 | Buy | $16.00 | +400.00% | Maintains | 3 months ago |
Aura Biosciences IncAURA | 6 | Buy | $25.00 | +281.10% | Maintains | 3 months ago |
Inflarx NvIFRX | 22 | Buy | $8.00 | +897.51% | Reiterates | 3 months ago |
Tg Therapeutics IncTGTX | 27 | Buy | $55.00 | +49.78% | Reiterates | 4 months ago |
Syndax Pharmaceuticals IncSNDX | 27 | Buy | $51.00 | +466.67% | Reiterates | 4 months ago |
Puma Biotechnology IncPBYI | 20 | Buy | $7.00 | +95.53% | Reiterates | 4 months ago |
Karyopharm Therapeutics IncKPTI | 28 | Buy | $56.00 | +1,175.63% | Maintains | 4 months ago |
Dynavax Technologies CorpDVAX | 20 | Buy | $31.00 | +201.85% | Reiterates | 4 months ago |
Chimerix IncCMRX | 14 | Buy | $11.00 | +28.81% | Reiterates | 5 months ago |
Lumos Pharma IncLUMO | 14 | Hold | $4.25 | -2.07% | Reiterates | 8 months ago |
Inhibikase Therapeutics IncIKT | 9 | Buy | $5.00 | +164.55% | Maintains | 9 months ago |
Adicet Bio IncACET | 14 | Buy | $10.00 | +1,547.45% | Reiterates | a year ago |
G1 Therapeutics IncGTHX | 13 | Buy | $3.00 | N/A | Maintains | a year ago |
Tracon Pharmaceuticals IncTCON | 11 | Buy | $60.00 | N/A | Maintains | a year ago |
Crescent Biopharma IncCBIO | 8 | Buy | $8.00 | N/A | Maintains | a year ago |
Bolt Biotherapeutics IncBOLT | 8 | Buy | $160.00 | N/A | Maintains | a year ago |
Spyre Therapeutics IncSYRE | 7 | Hold | $25.00 | N/A | Maintains | 2 years ago |
Spectrum Pharmaceuticals IncSPPI | 6 | Buy | $4.00 | N/A | Reiterates | 2 years ago |
Chemocentryx IncCCXI | 2 | Hold | $52.00 | N/A | Downgrades | 3 years ago |
Rein Therapeutics IncRNTX | 4 | Buy | $20.00 | N/A | Maintains | 3 years ago |
Vyant Bio IncVYNT | 3 | Buy | $15.00 | N/A | Maintains | 3 years ago |
Clovis Oncology IncCLVSQ | 5 | Hold | N/A | N/A | Downgrades | 3 years ago |
Ars Pharmaceuticals IncSPRY | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Allena Pharmaceuticals IncALNAQ | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Acceleron Pharma IncXLRN | 3 | Hold | $180.00 | N/A | Downgrades | 4 years ago |
Mersana Therapeutics IncMRSN | 1 | Buy | $28.00 | N/A | Initiates Coverage On | 4 years ago |
Ideaya Biosciences IncIDYA | 4 | Buy | $30.00 | N/A | Maintains | 4 years ago |
Mirati Therapeutics IncMRTX | 8 | Buy | $247.00 | N/A | Maintains | 4 years ago |
Celyad Oncology SaCYADY | 3 | Buy | $15.00 | N/A | Maintains | 4 years ago |
Arqule IncARQL | 1 | Hold | $20.00 | N/A | Downgrades | 6 years ago |
La Jolla Pharmaceutical CoLJPC | 1 | Buy | $62.00 | N/A | Initiates Coverage On | 8 years ago |
Fate Therapeutics IncFATE | 1 | Buy | $7.00 | N/A | Assumes | 8 years ago |
Tesaro IncTSRO | 2 | Buy | $158.00 | N/A | Initiates Coverage On | 8 years ago |
Kindred Biosciences IncKIN | 1 | Buy | $10.00 | N/A | Initiates Coverage On | 8 years ago |